Antibodies binding to α7β1 integrin antibodies and compositions thereof
US12134642B2 · kind B2 · utility
0Cited by
13References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 13, 2020 |
| Grant date | Nov 5, 2024 |
| Priority date | — |
| Expiry date | Apr 17, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.